Molly Henderson - Jan 18, 2024 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
CFO and CBO
Signature
/s/ Larry Miller, Attorney-in-Fact for Molly Henderson
Stock symbol
PHAT
Transactions as of
Jan 18, 2024
Transactions value $
-$48,900
Form type
4
Date filed
1/22/2024, 08:22 PM
Previous filing
Nov 21, 2023
Next filing
Apr 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Sale -$48.9K -6.31K -6.01% $7.75 98.7K Jan 19, 2024 Direct F1, F2
holding PHAT Common Stock 1.91K Jan 18, 2024 By 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option (Right to Buy) Award $0 +120K $0.00 120K Jan 18, 2024 Common Stock 120K $7.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2 Includes 1,944 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024.
F3 The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.